Carcinogenicity studies in rodents and ripazepam, a minor tranquilizing agent

Area of Science:

• Toxicology
• Carcinogenesis Studies
• Pharmacology

Background:

• Benzodiazepines are commonly prescribed psychoactive medications.
• Understanding the long-term safety profile of benzodiazepine derivatives is crucial.
• Ripazepam is a derivative of benzodiazepine with unknown carcinogenic potential.

Purpose of the Study:

• To evaluate the potential for ripazepam to cause cancer in rodents.
• To assess the dose-response relationship of ripazepam in long-term carcinogenicity studies.
• To identify any specific tumor types associated with ripazepam exposure.

Main Methods:

• Carcinogenesis bioassays were conducted in CD1 mice and CD rats.
• Animals were administered ripazepam orally via diet for 78 weeks (mice) and 104 weeks (rats).
• Dose levels were 15 and 150 mg/kg/day, with adequate survival for statistical analysis.

Main Results:

• Ripazepam did not increase tumor incidence in rats or alter neoplasm latency.
• A significant increase in hepatocellular tumors was observed in male rats at 150 mg/kg.
• Hepatocellular tumors showed a non-significant increase in female mice; most were benign adenomas.

Conclusions:

• Ripazepam does not appear to be a general carcinogen in rats.
• A specific risk of hepatocellular tumors exists in male rats at high doses.
• Further investigation may be warranted for hepatic effects in rodents.